SOURCE: TomoTherapy

TomoTherapy

November 10, 2010 09:20 ET

TomoTherapy Charity Event at ASTRO Raises $15,000

More Than 700 Attend "Better Bash" With Proceeds Benefiting The Leukemia & Lymphoma Society and Radiate Hope Foundation

MADISON, WI--(Marketwire - November 10, 2010) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that the company raised more than $15,000 at a benefit for The Leukemia & Lymphoma Society and Radiate Hope Foundation. More than 700 supporters attended the "Better Bash" charity event in San Diego, Calif., during last week's 52nd annual meeting of the American Society for Radiation Oncology (ASTRO).

Special guests included off-road racing champion Joe Bacal, who was treated with TomoTherapy technology for Hodgkin's lymphoma in 2007, and Carol Ramnarine, a multiple myeloma survivor who became the first person worldwide to undergo total marrow irradiation, a highly-targeted form of radiation therapy made possible only through the use of the TomoTherapy treatment system.

"Having a strong support base is very important to beating cancer," said Bacal, who is currently in training for the Baja 1000 race, which begins November 17. "It was great to see so many people come out to support survivors like Carol and me, who benefit directly from the great work of TomoTherapy, as well as The Leukemia & Lymphoma Society and Radiate Hope."

The Leukemia & Lymphoma Society is the world's largest voluntary health agency dedicated to blood cancer. The Radiate Hope Foundation is a non-profit dedicated to engaging the community and providing hope to improve the lives of everyone affected by cancer. The Radiate Hope Foundation was founded in 2007 by TomoTherapy employee Brad Lobner, and has since raised more than $175,000 for organizations that work directly with cancer patients and survivors.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions includes its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    608.824.2800
    Email Contact

    Media Contacts:
    Kevin O'Malley
    Manager, Corporate Communications
    608.824.3384
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    510.832.6006
    Email Contact